Deep brain stimulation of the subthalamic nucleus in obsessive-compulsives disorders: long-term follow-up of an open, prospective, observational cohort.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
12 2020
Historique:
received: 05 04 2020
revised: 01 07 2020
accepted: 31 08 2020
pubmed: 10 10 2020
medline: 23 3 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

Obsessive-compulsive disorder (OCD) is a major cause of disability in western country and responsible for severe impairment of quality of life. About 10% of patients present with severe OCD symptoms and require innovative treatment such as deep brain stimulation (DBS). Among possible targets, the non-motor subthalamic nucleus (STN) is a key node of the basal ganglia circuitry, strongly connected to limbic cortical areas known to be involved in OCD. We analysed, in a prospective, observational, monocentric, open label cohort, the effect of chronic non-motor STN-DBS in 19 patients with treatment-resistant OCD consecutively operated in a single centre. Severity of OCD was evaluated using the Yale and Brown Obsessive-Compulsive Scale (YBOCS). YBOCS scores at 6, 12 and 24 months postoperatively were compared with baseline. Responders were defined by >35% improvement of YBOCS scores. Global Assessment Functioning (GAF) scale was used to evaluate the impact of improvement. At a 24-month follow-up, the mean YBOCS score improved by 53.4% from 33.3±3.5 to 15.8±9.1 (95% CI 11.2-20.4; p<0.0001). Fourteen out of 19 patients were considered as responders, 5 out of 19 being improved over 75% and 10 out of 19 over 50%. GAF scale improved by 92% from 34.1±3.9 to 66.4±18.8 (95% CI 56.7-76.1; p=0.0003). The most frequent adverse events consisted of transient DBS-induced hypomania and anxiety. Chronic DBS of the non-motor STN is an effective and relatively safe procedure to treat severe OCD resistant to conventional management.

Sections du résumé

BACKGROUND
Obsessive-compulsive disorder (OCD) is a major cause of disability in western country and responsible for severe impairment of quality of life. About 10% of patients present with severe OCD symptoms and require innovative treatment such as deep brain stimulation (DBS). Among possible targets, the non-motor subthalamic nucleus (STN) is a key node of the basal ganglia circuitry, strongly connected to limbic cortical areas known to be involved in OCD.
METHOD
We analysed, in a prospective, observational, monocentric, open label cohort, the effect of chronic non-motor STN-DBS in 19 patients with treatment-resistant OCD consecutively operated in a single centre. Severity of OCD was evaluated using the Yale and Brown Obsessive-Compulsive Scale (YBOCS). YBOCS scores at 6, 12 and 24 months postoperatively were compared with baseline. Responders were defined by >35% improvement of YBOCS scores. Global Assessment Functioning (GAF) scale was used to evaluate the impact of improvement.
RESULTS
At a 24-month follow-up, the mean YBOCS score improved by 53.4% from 33.3±3.5 to 15.8±9.1 (95% CI 11.2-20.4; p<0.0001). Fourteen out of 19 patients were considered as responders, 5 out of 19 being improved over 75% and 10 out of 19 over 50%. GAF scale improved by 92% from 34.1±3.9 to 66.4±18.8 (95% CI 56.7-76.1; p=0.0003). The most frequent adverse events consisted of transient DBS-induced hypomania and anxiety.
CONCLUSION
Chronic DBS of the non-motor STN is an effective and relatively safe procedure to treat severe OCD resistant to conventional management.

Identifiants

pubmed: 33033168
pii: jnnp-2020-323421
doi: 10.1136/jnnp-2020-323421
pmc: PMC7677463
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1349-1356

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Trends Neurosci. 1989 Oct;12(10):366-75
pubmed: 2479133
Mov Disord. 2015 Feb;30(2):128-40
pubmed: 25297382
Brain Stimul. 2019 Jul - Aug;12(4):1080-1082
pubmed: 30992192
Neurology. 2006 Jan 10;66(1):142-3
pubmed: 16401868
Compr Psychiatry. 2008 Jan-Feb;49(1):43-50
pubmed: 18063040
Psychiatr Clin North Am. 1992 Dec;15(4):743-58
pubmed: 1461792
Biol Psychiatry. 2014 Apr 15;75(8):595-605
pubmed: 24314349
Transl Psychiatry. 2019 Feb 4;9(1):73
pubmed: 30718450
Mol Psychiatry. 2017 Nov;22(11):1626-1632
pubmed: 27431293
Brain. 2017 Feb;140(2):442-456
pubmed: 28040671
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10661-6
pubmed: 17556546
Mol Psychiatry. 2016 Sep;21(9):1272-80
pubmed: 26303665
Neuroimage. 2007 Jan 15;34(2):618-38
pubmed: 17110133
Lancet. 1999 Oct 30;354(9189):1526
pubmed: 10551504
J Neurosurg. 2004 Jun;100(6):1084-6
pubmed: 15200126
Mol Psychiatry. 2017 Jun;22(6):931-934
pubmed: 27480493
Epileptic Disord. 2002 Dec;4 Suppl 3:S83-93
pubmed: 12495878
Lancet Neurol. 2014 Mar;13(3):287-305
pubmed: 24556007
Neuropsychopharmacology. 2010 Jan;35(1):317-36
pubmed: 19759530
Neurology. 2019 Jul 2;93(1):e97-e105
pubmed: 31101738
Prog Neurobiol. 2004 Feb;72(3):195-221
pubmed: 15130710
Lancet Neurol. 2009 Jan;8(1):67-81
pubmed: 19081516
Biol Psychiatry. 2019 May 1;85(9):726-734
pubmed: 30853111
Psychiatr Clin North Am. 2006 Jun;29(2):553-84, xi
pubmed: 16650723
Arch Gen Psychiatry. 2010 Oct;67(10):1061-8
pubmed: 20921122
Am J Psychiatry. 1986 Mar;143(3):317-22
pubmed: 3953865
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jun;3(6):563-571
pubmed: 29550459
Neurology. 2016 Oct 25;87(17):1843-1844
pubmed: 27655738
Lancet. 2002 Oct 26;360(9342):1302-4
pubmed: 12414208
J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1113-8
pubmed: 23667214
Mov Disord. 2014 Mar;29(3):305
pubmed: 24375493
JAMA Psychiatry. 2013 Jun;70(6):619-29
pubmed: 23740050
J Neurosci. 2013 Mar 13;33(11):4804-14
pubmed: 23486951
N Engl J Med. 2008 Nov 13;359(20):2121-34
pubmed: 19005196
PLoS One. 2015 Aug 27;10(8):e0135524
pubmed: 26312488
Brain Stimul. 2015 Mar-Apr;8(2):177-84
pubmed: 25511796
Arch Gen Psychiatry. 2004 Jun;61(6):564-76
pubmed: 15184236
PLoS One. 2015 Jul 24;10(7):e0133591
pubmed: 26208305
Ann Neurol. 2011 May;69(5):793-802
pubmed: 21520240
World Neurosurg. 2013 Sep-Oct;80(3-4):S31.e1-8
pubmed: 22469523

Auteurs

Stephan Chabardes (S)

CLINATEC, CEA Clinatec-Minatec, Grenoble, France schabardes@chu-grenoble.fr.
Department of Neurosurgery, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Grenoble Institut neurosciences, University Grenoble Alpes-INSERM U1216, 38000 Grenoble, France.

Paul Krack (P)

Division of Neurology, Department of Neurology, Bern University Hospital, Bern, Switzerland, Bern, Switzerland.
Department of Neurology, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Brigitte Piallat (B)

Grenoble Institut neurosciences, University Grenoble Alpes-INSERM U1216, 38000 Grenoble, France.

Thierry Bougerol (T)

Department of Psychiatry, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Eric Seigneuret (E)

Department of Neurosurgery, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Jerome Yelnik (J)

Institut du Cerveau, ICM, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, F-75013, Paris, France.

Sara Fernandez Vidal (S)

Institut du Cerveau, ICM, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, F-75013, Paris, France.

Olivier David (O)

Grenoble Institut neurosciences, University Grenoble Alpes-INSERM U1216, 38000 Grenoble, France.

Luc Mallet (L)

Institut du Cerveau, ICM, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, F-75013, Paris, France.
Département Médical-Universitaire de Psychiatrie et d'Addictologie, Univ Paris-Est Créteil, DMU IMPACT, Hôpitaux Universitaires Henri Mondor - Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Department of Mental Health and Psychiatry, Global Health Institute, University of Geneva, Geneva, Switzerland.

Alim-Louis Benabid (AL)

CLINATEC, CEA Clinatec-Minatec, Grenoble, France.

Mircea Polosan (M)

Grenoble Institut neurosciences, University Grenoble Alpes-INSERM U1216, 38000 Grenoble, France.
Department of Psychiatry, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH